COMPANY PROFILE

Ovagen

A company developing a proprietary process of producing Germ Free chicken eggs and Germ Free birds in commercial quantities for use primarily in the pharmaceutical industry

Ballina, IrelandFounded 2000Biotech & Life Sciences

Valuation $25–50M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Ovagen

Operator of a veterinary company intended to develop a process of producing germ-free eggs in commercial quantities used primarily in pharmaceutical industries. The company's process facilitates large-scale production of recombinant proteins to GMP standard using a transgenic chicken platform, enabling pharmaceutical companies to have a safe, biosecure, large-scale, flexible, and cost-effective biomanufacturing platform for the production of vaccines and therapeutic proteins. Keywords: Pharmaceuticals and Biotechnology, Antibody Service, Bacterial Free Egg, Bio Manufacturing Platform, Germ Free, Poultry Husbandry, Production Process, Therapeutic Protein.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2000
Headquarters: Ballina, Ireland
Employees: 10
Open positions: None listed
Dealroom signal: 57.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, EIC, Tech for Biotech and Pharma, Biotech and Pharma, Biotechnology in Food, Horizon Europe, biomanufacturing, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Oct 2024	$2.2M	$41M	Enterprise Ireland · Halo Business Angel Network · Spark Crowdfunding · Boole	↗
FundingOther financing	Jun 2024	$100K	—	Enterprise Ireland	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	EBITDA	Margin
2026		—
2025		—
2024		—
2023		—
2022		—
2021		—
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Ovagen website traffic

Latest recorded traffic for Ovagen is 7.1K monthly website visits, up 44.9% over the last three months. Ovagen's team declined 9.1% over the past year.

Latest monthly visits7.1K 3-month web change+44.9% 1-year team growth-9.1%

Monthly website visitsJan 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational	17	$98M	$367M
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
NENeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment	Kearny, United States	Operational
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
NDNovus DiagnosticsDeveloping ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside	Dublin, Ireland	Operational
IMIMMUNETHEPBiotech start-up company that is developing broad coverage anti-bacterial immunotherapies	Cantanhede, Portugal	Operational
FBFOx BiosystemsFox biosystems produces fiber-optic biosensor instruments	Diepenbeek, Belgium	Operational